je.st
news
Tag: evaluating
Evaluating Emerson Electric's Earnings Quality And ROE
2015-07-13 10:19:43| Electronics - Topix.net
Emerson Electric has been covered extensively on Seeking Alpha over the last few months. A few contributors have put out some excellent articles recently, and they've largely swayed me towards this industrial company with a 58 year dividend growth streak.
Tags: quality
earnings
evaluating
emerson
BB&T evaluating office space needs in uptown Charlotte
2015-06-09 01:57:36| Industrial Machines - Topix.net
BB&T Corp. is evaluating its office space in uptown Charlotte, where the Winston Salem-based financial-services company occupies a large block of space at the BB&T Center on College street. BB&T currently occupies approximately 140,000 square feet on multiple floors at BB&T Center.
Tags: office
space
charlotte
evaluating
San Antonio firms are evaluating supply chains for 'conflict minerals'
2015-06-03 14:46:41| Industrial Machines - Topix.net
Two publicly-traded companies from San Antonio are working to make sure their supply chains are free of minerals from conflict zones in Central Africa.
Tags: san
supply
antonio
firms
First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Mercks KEYTRUDA (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine
2015-05-29 20:05:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Early Findings Show DNA Mismatch Repair-Deficient Colorectal and Other Tumors Highly Responsive to Checkpoint Blockade with Anti-PD-1 Therapy Merck Plans to Initiate Phase 2 Registrational Study with KEYTRUDA (KEYNOTE-164) to Evaluate MMR-Deficiency in Colorectal Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the first study evaluating the correlation of benefit with an immunotherapy based on DNA mismatch repair (MMR) deficiency, a well-established form of genetic instability in many cancers characterized by the loss of function of the MMR pathway. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen
2015-05-07 14:30:00| Merck.com - Product News
Dateline City: BERKELEY, Calif., and KENILWORTH, N.J. Study will Evaluate Mercks Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), in Combination with Plexxikons PLX3397 BERKELEY, Calif., and KENILWORTH, N.J. May 7, 2015 Plexxikon Inc., a member of Daiichi Sankyo Group, and Merck (NYSE:MRK), known as MSD outside the US and Canada, through a subsidiary, today announced a collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikons investigational CSF-1R inhibitor, and KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, which provides the potential for a double blockade of cancer-induced immune suppression. Language: English read more
Tags: study
combination
evaluating
collaborate
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »